Literature DB >> 9310341

Overexpression of the multidrug resistance genes mdr1, mdr3, and mrp in L1210 leukemia cells resistant to inhibitors of ribonucleotide reductase.

G Rappa1, A Lorico, M C Liu, G D Kruh, A H Cory, J G Cory, A C Sartorelli.   

Abstract

L1210 MQ-580 is a murine leukemia cell line resistant to the cytotoxic activity of the alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazone class of inhibitors of ribonucleotide reductase. The line is cross-resistant to etoposide, daunomycin, and vinblastine. L1210 MQ-580 cells expressed 8-fold resistance to 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP), a relatively newly developed inhibitor of ribonucleotide reductase. The accumulation of [14C]3-AP by L1210 MQ-580 cells was 5- to 6-fold less than by parental L1210 cells. An increased rate of efflux of 3-AP was responsible for the lower steady-state concentration of 3-AP in resistant cells. In reverse transcription-polymerase chain reaction assays, L1210 MQ-580 cells were found to overexpress the multidrug resistance genes mdr1, mdr3, and mrp, but not the mdr2 gene, compared with parental L1210 cells. Measurement of the steady-state concentration of doxorubicin, a potential substrate for both the mdr and mrp gene products, demonstrated that L1210 MQ-580 cells accumulated 4-fold less anthracycline than parental cells. These findings indicate that drug efflux is a major determinant of the pattern of cross-resistance of L1210 MQ-580 cells. To extrapolate these observations to the human homologues of the mdr1, mdr3, and mrp murine genes, the effects of 3-AP were measured in L1210/VMDRC0.06 and NIH3T3 36-8-32 cells transfected with human MDR1 and MRP cDNAs, respectively. The transfectants were 2- to 3-fold resistant to the cytotoxic effects of 3-AP and accumulated less [14C]3-AP than their parental mock-transfected counterparts. Moreover, the cytotoxic activity of 3-AP was significantly greater in two double mrp gene knockout cell lines than in parental W 9.5 embryonic stem cells. Thus, the results suggest that 3-AP is a substrate for both the P-glycoprotein and MRP and that baseline MRP expression has the capacity to exert a protective role against the toxicity of this agent.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9310341     DOI: 10.1016/s0006-2952(97)00210-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  Identification of compounds selectively killing multidrug-resistant cancer cells.

Authors:  Dóra Türk; Matthew D Hall; Benjamin F Chu; Joseph A Ludwig; Henry M Fales; Michael M Gottesman; Gergely Szakács
Journal:  Cancer Res       Date:  2009-10-20       Impact factor: 12.701

2.  Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.

Authors:  Jill Kolesar; Richard C Brundage; Marcia Pomplun; Dona Alberti; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-04       Impact factor: 3.333

3.  The molecular interaction of a copper chelate with human P-glycoprotein.

Authors:  Ruma Dey Ghosh; Paramita Chakraborty; Kaushik Banerjee; Arghya Adhikary; Avijit Sarkar; Mitali Chatterjee; Tanya Das; Soumitra Kumar Choudhuri
Journal:  Mol Cell Biochem       Date:  2012-01-19       Impact factor: 3.396

4.  A phase II trial of triapine (NSC# 663249) and gemcitabine as second line treatment of advanced non-small cell lung cancer: Eastern Cooperative Oncology Group Study 1503.

Authors:  Anne M Traynor; Ju-Whei Lee; Gerald K Bayer; John M Tate; Sachdev P Thomas; Miroslaw Mazurczak; David L Graham; Jill M Kolesar; Joan H Schiller
Journal:  Invest New Drugs       Date:  2009-02-24       Impact factor: 3.850

5.  Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

Authors:  Joseph A Ludwig; Gergely Szakács; Scott E Martin; Benjamin F Chu; Carol Cardarelli; Zuben E Sauna; Natasha J Caplen; Henry M Fales; Suresh V Ambudkar; John N Weinstein; Michael M Gottesman
Journal:  Cancer Res       Date:  2006-05-01       Impact factor: 12.701

Review 6.  Is resistance useless? Multidrug resistance and collateral sensitivity.

Authors:  Matthew D Hall; Misty D Handley; Michael M Gottesman
Journal:  Trends Pharmacol Sci       Date:  2009-09-15       Impact factor: 14.819

7.  A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Authors:  Steven Attia; Jill Kolesar; Michelle R Mahoney; Henry C Pitot; Daniel Laheru; James Heun; Wei Huang; Jens Eickhoff; Charles Erlichman; Kyle D Holen
Journal:  Invest New Drugs       Date:  2008-02-16       Impact factor: 3.850

8.  Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells.

Authors:  Matthew D Hall; Noeris K Salam; Jennifer L Hellawell; Henry M Fales; Caroline B Kensler; Joseph A Ludwig; Gergely Szakács; David E Hibbs; Michael M Gottesman
Journal:  J Med Chem       Date:  2009-05-28       Impact factor: 7.446

9.  Synthesis and characterization of new copper thiosemicarbazone complexes with an ONNS quadridentate system: cell growth inhibition, S-phase cell cycle arrest and proapoptotic activities on cisplatin-resistant neuroblastoma cells.

Authors:  Haiyuan Zhang; Ronald Thomas; David Oupicky; Fangyu Peng
Journal:  J Biol Inorg Chem       Date:  2007-10-02       Impact factor: 3.358

10.  P-glycoprotein efflux pump plays an important role in Trypanosoma cruzi drug resistance.

Authors:  Mônica Caroline Oliveira Campos; Denise Barçante Castro-Pinto; Grazielle Alves Ribeiro; Márcia Moreira Berredo-Pinho; Leonardo Henrique Ferreira Gomes; Myrtes Santos da Silva Bellieny; Carla Marins Goulart; Aurea Echevarria; Leonor Laura Leon
Journal:  Parasitol Res       Date:  2013-04-10       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.